account_balance
Investment manager · 13F filer · SEC CIK 1766721
Aisling Capital Management LP
Reported value$299Mas of Sep 30, 2026
Positions14 0 new, 0 sold out
Top 10 weight98.5%BBIO alone is 68%
FiledNov 1243 days after quarter end
Portfolio · as of Sep 30, 2026
Where the money is
New or addedTrimmedHeld
BBIOBridgebio Pharma Inc
67.9%Trimmed −33%
SNDXSyndax Pharmaceuticals Inc
8.3%
CMPSCompass Pathways PLC
7.2%Added +21%
GLUEMonte Rosa Therapeutics Inc
6.2%
BCAXBicara Therapeutics Inc
3.4%Trimmed −4%
URGN1.5%BBOT1.4%EPRX1.0%BMEA0.9%ACRS0.8%SRRK0.7%VTVT0.6%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
BBIO Bridgebio Pharma Inc 67.9% Trimmed −33%SNDX Syndax Pharmaceuticals Inc 8.3% HeldCMPS Compass Pathways PLC 7.2% Added +21%GLUE Monte Rosa Therapeutics Inc 6.2% HeldBCAX Bicara Therapeutics Inc 3.4% Trimmed −4%URGN Urogen Pharma Ltd 1.5% HeldBBOT Bridgebio Oncology Therapeut 1.4% HeldEPRX Eupraxia Pharmaceuticals Inc 1.0% HeldBMEA Biomea Fusion Inc 0.9% HeldACRS Aclaris Therapeutics Inc 0.8% HeldSRRK Scholar Rock HLDG Corp 0.7% Trimmed −45%VTVT VTV Therapeutics Inc 0.6% Added +18%
What changed